Immunoforge specializes in novel drug development based on elastin-like polypeptide (ELP) platform technology, focusing on creating first-in-class drugs for rare and intractable diseases, including muscular dystrophies, autoimmune diseases, and cancers
Immunoforge specializes in novel drug development based on elastin-like polypeptide (ELP) platform technology, focusing on creating first-in-class drugs for rare and intractable diseases, including muscular dystrophies, autoimmune diseases, and cancers.